Question follow-through · 18222
Sunscreens: VAT
To ask the Chancellor of the Exchequer, what assessment she has made of the potential impact of removing VAT from sunscreen products on public health outcomes; and whether she plans to reclassify sunscreen products with SPF protection as essential health
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Treasury
- Tabled
- 13 Jul 2026
- Target answer date
- 15 Jul 2026
- Answer
- 16 Jul 2026 · 3 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
13 Jul 2026
Question tabled
To ask the Chancellor of the Exchequer, what assessment she has made of the potential impact of removing VAT from sunscreen products on public health outcomes; and whether she plans to reclassify sunscreen products with SPF protection as essential health
15 Jul 2026
Target answer date
Date supplied by the official written-questions record.
16 Jul 2026
Answer published
VAT rules do allow drugs and medications that are dispensed by a registered pharmacist against a prescription issued by a qualifying health professional to be zero rated for VAT. High-factor sunscreen is already on the NHS prescription list for certain co...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.